The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
本发明涉及一种式(I)化合物:及其药学上可接受的盐、溶液剂、水合物或立体异构体,可用于治疗或预防由过氧化物酶体增殖物激活受体(PPAR)介导的疾病,如 X 综合征、II 型糖尿病、高血糖、高脂血症、肥胖、凝血功能障碍、高血压、动脉硬化以及其他与 X 综合征和心血管疾病相关的疾病。
SULFONAMIDE DERIVATIVES AS PPAR MODULATORS
申请人:ELI LILLY AND COMPANY
公开号:EP1597248A2
公开(公告)日:2005-11-23
US7655641B2
申请人:——
公开号:US7655641B2
公开(公告)日:2010-02-02
[EN] SULFONAMIDE DERIVATIVES AS PPAR MODULATORS<br/>[FR] DERIVES DE SULFONAMIDES UTILISES COMME MODULATEURS DU RECEPTEUR PPAR
申请人:LILLY CO ELI
公开号:WO2004073606A2
公开(公告)日:2004-09-02
The present invention is directed to a compound of Formula (I):, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
Positive variation of the MRI signal via intramolecular inclusion complexation of a C-2 functionalized β-cyclodextrin
complexes were known to undergo an enhancement of the contrast imaging. We extend this concept to intramolecular complexation. Inter- and intramolecular interactions are compared by NMR spectroscopy, circulardichroism and magnetic resonance imaging using hydrocinnamic acid and adamantane carboxylic acid as external guests. This positive variation of the observed relaxivity is a key element of new strategies